EFFICACY OF GUSELKUMAB ACROSS BASDAI COMPONENTS IN TREATING AXIAL-RELATED SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE-3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES

被引：0
|
作者：
Behrens, F. [1 ]
Mease, P. J. [2 ]
Helliwell, P. S. [3 ]
Shawi, M. [4 ]
Noel, W. [5 ]
Chakravarty, S. D. [4 ,6 ]
Kollmeier, A. P. [4 ]
Xu, X. L. [4 ]
Xu, S. [4 ]
Wang, Y. [4 ]
Baraliakos, X. [7 ]
机构：
[1] Goethe Univ, Frankfurt, Germany
[2] Univ Washington, Swedish Med Ctr, Seattle, WA 98195 USA
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Janssen R&D, Township, PA USA
[5] Janssen R&D, Beerse, Belgium
[6] Drexel Univ, Philadelphia, PA 19104 USA
[7] Ruhr Univ Bochum, Bochum, Germany
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2021年 / 39卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P158
引用
收藏
页码：1244 / 1245
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
    Dafna D. Gladman
    Philip J. Mease
    Paul Bird
    Enrique R. Soriano
    Soumya D. Chakravarty
    May Shawi
    Stephen Xu
    Sean T. Quinn
    Cinty Gong
    Evan Leibowitz
    Denis Poddubnyy
    Lai-Shan Tam
    Philip S. Helliwell
    Arthur Kavanaugh
    Atul Deodhar
    Mikkel Østergaard
    Xenofon Baraliakos
    Trials, 23
  • [42] Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Ritchlin, Christopher
    Lubrano, Ennio
    Chimenti, Maria Sole
    Leibowitz, Evan
    Sharaf, Mohamed
    Adelakun, Oyediran
    Rampakakis, Emmanouil
    Nantel, Francois
    Lavie, Frederic
    Deodhar, Atul
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2999 - 3001
  • [43] Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study
    Deodhar, Atul
    Supronik, Jerzy
    Kivitz, Alan
    Valenzuela, Guillermo
    Kapur, Karen
    Rohrer, Susanne
    Dokoupilova, Eva
    Richards, Hanno B.
    Pavelka, Karel
    ARTHRITIS & RHEUMATOLOGY, 2024,
  • [44] Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial
    Elewski, B. E.
    Baker, C. S.
    Crowley, J. J.
    Poulin, Y.
    Okun, M. M.
    Calimlim, B.
    Geng, Z.
    Servin, O. Reyes
    Rich, P. A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (11) : 2168 - 2178
  • [45] Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
    Mease, Philip
    Helliwell, Philip S.
    Gladman, Dafna
    Poddubnyy, Denis
    Baraliakos, Xenofon
    Chakravarty, Soumya
    Kollmeier, Alexa
    Xu, Xie
    Sheng, Shihong
    Xu, Stephen
    Shawi, May
    van der Heijde, Desiree
    Deodhar, Atul
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2760 - 2763
  • [46] Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a Phase-3, randomized, placebo-controlled trial
    Elewski, B. E.
    Rich, P. A.
    Okun, M. M.
    Papp, K.
    Baker, C. S.
    Crowley, J. J.
    Guillet, G.
    Gu, Y.
    Geng, Z.
    Sundaram, M.
    Williams, D. A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 65 - 65
  • [47] Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Eder, Lihi
    Selmi, Carlo
    Mease, Philip
    Ogdie, Alexis
    Nantel, Francois
    Lavie, Frederic
    Sharaf, Mohamed
    Adelakun, Oyediran
    Rampakakis, Emmanouil
    Vegas, Laura Pina
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4720 - 4722
  • [48] Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial
    Gossec, Laure
    Kirkham, Bruce
    Rahman, Proton
    Helliwell, Philip
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Han, Chenglong
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [49] Validation of the PROMIS-29 Profile in Patients with Active Psoriatic Arthritis Using Data from a Phase 3, Randomized, Placebo-Controlled Study Evaluating Guselkumab (TREMFYA®)
    Orbai, Ana-Maria
    Coates, Laura
    Deodhar, Atul
    Ritchlin, Christopher
    Kollmeier, Alexa
    Neuhold, Marlies
    Liu, Yi-Hsuan
    Liu, Yan
    Han, Chenglong
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2766 - 2769
  • [50] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKS FROM A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Deodhar, A.
    Gottlieb, A. B.
    Boehricke, W-H.
    Dong, B.
    Wang, Y.
    Zhuang, Y.
    Barchuk, W.
    Xu, X. L.
    Hsia, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 201 - 201
12345